Mitochondrial dysfunction and energy changes of black-substance neurons in experimental parkinson's disease in rats and mothors

Abstract

Parkinson's disease is a progressive disease with moderate age of the beginning of 55 years. Over time, symptoms worsen, and although levodopa has significantly improved the quality of life of patients with PD, statistics show that these patients continue to show shorter life expectancies compared to the general population. In addition, most patients with PD suffer from significant movement disorders after 5–10 years of illness, even with qualified treatment with available symptomatic drugs.

Keywords

• mitochondrial dysfunction
• energy deficiency
• energy potential
• neuroprotective therapy